A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease

Study acronym: PrevenTRON
StatusRecruiting
PhasePhase 3
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary endpoints: details revised at 1 of 1 entry
    • Trial sites expanded: 7 → 34 locations
    • Eligibility criteria expanded, about 34 words
    • Secondary endpoints: details revised at 1 of 19 entries
  2. Recruitment opened
    • Trial sites expanded: 0 → 7 locations
    v2
  3. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Roche/Genentech
367 trials monitored
See 31 trials at risk
Dementia
1,982 trials monitored
See 105 trials at risk
Alzheimer's Disease
1,255 trials monitored
See 68 trials at risk
This study will evaluate the efficacy and safety of trontinemab in participants with biomarker evidence of Alzheimer's Disease (AD) pathology but with no cognitive or functional impairment, who are at risk for progression to mild cognitive impairment (MCI) due to AD or dementia due to AD.
Trial Details
NCT Number NCT07717411
Lead Sponsor Hoffmann-La Roche
Conditions
(from sponsor)		 Alzheimer's Disease
Related terms Alzheimer Disease
Enrollment 1,600 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov